Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
Andy Studna
Advertisement
Articles by Andy Studna
Advertisement
Latest Updated Articles
Efsitora Alfa, Eli Lilly’s Once Weekly Insulin, Has Positive Topline Results in Two TrialsPublished: September 6th 2024 | Updated:
Teal Health Granted Breakthrough Device Designation for Self-Collect Cervical Cancer Screening DevicePublished: May 14th 2024 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission
2
Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk
3
FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps
4
